Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07735793 | A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in Korea(BC RC DB) | not yet recruiting | — | 1 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | not yet recruiting | Phase 1 | 18 | ImmunityBio, Inc.INDUSTRY | 1 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07829783 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)(TroFuse-055) | not yet recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2026 | clinicaltrials |
| NCT06227065 | Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids(POLO) | not yet recruiting | Phase 2 | 28 | Hospital Centre Biel/BienneOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827612 | A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer(FORAY) | not yet recruiting | Phase 2 | 161 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07332351 | Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial(TRIFECTA) | not yet recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07822373 | A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer(PRESERVE) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07777848 | A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC). | not yet recruiting | Phase 2 | 114 | Ractigen Therapeutics.OTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07817173 | Feasibility of HISA During TURBT for NMIBC | not yet recruiting | N/A | 40 | CAMC Health SystemOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study(OHAI-NMIBC-01) | not yet recruiting | Phase 2 | 106 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | not yet recruiting | Phase 2 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07783815 | A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | not yet recruiting | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07781956 | Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application(NMIBC-HSC) | not yet recruiting | N/A | 40 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07762820 | REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors(RETRIEVE-BT) | not yet recruiting | N/A | 75 | Ludwig-Maximilians - University of MunichOTHER | 3 | Aug 17, 2026 | clinicaltrials |
| NCT07758881 | Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. | not yet recruiting | N/A | 30 | Eight Medical International BVINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07756008 | Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | not yet recruiting | Phase 2 / Phase 3 | 114 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07749924 | Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC | not yet recruiting | N/A | 670 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07724886 | Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC | not yet recruiting | N/A | 732 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07727343 | AI-Guided TURBT for Bladder Cancer(AITURBT) | not yet recruiting | N/A | 170 | Fudan UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07725796 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | not yet recruiting | Phase 1 | 30 | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07095751 | Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer | not yet recruiting | N/A | 60 | Chinese University of Hong KongOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07690878 | PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer | not yet recruiting | Phase 2 | 35 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07639983 | Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma | not yet recruiting | Phase 2 | 44 | Sheng TaiOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07260162 | Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)(PERSEVERANCE) | not yet recruiting | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07608224 | HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC(HOPE-07-MIBC) | not yet recruiting | Phase 2 / Phase 3 | 240 | West China HospitalOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07231809 | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients(HIVEC) | not yet recruiting | N/A | 50 | AC.TA. S.r.l.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07555756 | An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models | not yet recruiting | N/A | 1,080 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 2 | Apr 29, 2026 | clinicaltrials |
| NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial(CALCIFER) | not yet recruiting | Phase 1 | 20 | Juan Luis VásquezOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07529639 | Tumor Budding and T1 Substaging in Urothelial Bladder Cancer | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT07525349 | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07503795 | Outcomes of Definitive Radiotherapy for Bladder Cancer | not yet recruiting | — | 300 | Sohag UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07468838 | Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer(UroDNA) | not yet recruiting | — | 25 | Institut Cancerologie de l'OuestOTHER | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07445308 | The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. | not yet recruiting | Phase 1 / Phase 2 | 120 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 0 | Mar 3, 2026 | clinicaltrials |
| NCT07408830 | VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors(VATSIT) | not yet recruiting | N/A | 2,482 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07008833 | Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer(REDEMPTED) | not yet recruiting | N/A | 336 | Brazilian Clinical Research InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07346053 | The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer(Chrono-EVP) | not yet recruiting | Phase 3 | 224 | Guliz OzgunOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07043543 | Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)(BLADAPT) | not yet recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT07203989 | The Effect of Video Calls With Family Members During Operating Room Waiting on Stress, Anxiety, and Surgical Fear in Patients Undergoing Transurethral Resection of Bladder Tumor | not yet recruiting | N/A | 124 | Bitlis Eren UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204301 | Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study(Flexi-comfort) | not yet recruiting | N/A | 378 | Western University, CanadaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204496 | A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer(γδ-T-BLADDER) | not yet recruiting | — | 20 | Shanghai 10th People's HospitalOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials